Close menu




December 23rd, 2021 | 11:15 CET

Novavax, Sativa Wellness Group, Bayer - The next wave ignites

  • Cannabis
Photo credits: pixabay.com

There is great concern in society due to the Omicron variant. Reason enough for politicians to further tighten measures, even for the approximately 70% of fully vaccinated people in the Federal Republic. The federal and state governments decided on stricter contact restrictions, large events without spectators and a new vaccination target. By the end of January, a further 30 million booster, first and second vaccinations are to be achieved. As a result, vaccine manufacturers are experiencing another boom. Meanwhile, a new vaccine is coming to Germany to change the minds of vaccination skeptics.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: NOVAVAX INC. DL-_01 | US6700024010 , SATIVA WELLNESS GROUP INC | CA80403E1043 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Novavax - With momentum into the new year

    So now it is official, Europe is getting its fifth vaccine. Following a recommendation by the EU Medicines Agency (EMA) for the Novavax preparation, a fifth vaccine is coming onto the market in the EU. The vaccine is effective, safe, and of high quality, the European Medicines Agency (EMA) assessment says. In clinical trials, the efficacy of Novavax against the early virus variants was around 90%, but experience with the new Omicron variant is not yet available. The newly approved vaccine Nuvaxovid is being treated as a beacon of hope, which should encourage vaccination skeptics to take the shot. In contrast to the mRNA and vector substances, the Novavax vaccine is produced using a traditional process. The vaccine contains tiny particles composed of a laboratory-produced version of the spike protein of Sars-CoV-2. This technology, unlike mRNA, has been around for some time. It has been in use in the USA since 1986.

    As early as this summer, the EU Commission concluded a contract for the supply of a total of up to 200 million doses. It includes an option for 100 million doses for the years 2022 and 2023. According to the authority, the first tranche is to be sent to the member states as early as the beginning of 2022. For the first quarter of 2022 alone, participating states have ordered about 27 million units.

    Once approval has been granted, the US manufacturer will proceed directly to secure recurring revenue with booster vaccinations. A corresponding Phase III study is already underway. The trial will evaluate the safety and efficacy of a third dose of the Novavax vaccine. Following the approval, Novavax's share price dropped significantly and retreated to support at USD 190.00 due to profit-taking. The market capitalization is a whopping EUR 12.73 billion, and the share price has increased more than tenfold at its peak since the Corona breakout in March 2020.

    Sativa Wellness - Attractive portfolio

    A broadly diversified and attractive portfolio is held by the Canadian Company Sativa Wellness, which has branches in the UK. The group is focusing on the rapidly growing cannabis business due to legalization and is pursuing the ambitious goal of becoming one of the leading producers of high-quality CBD products and CBD services in Europe.

    Due to a realignment and a strictly separated 3-pillar model, the Company achieved an impressive turnaround in the past year. Under Goodbody Botanicals, CBD products developed on a gold standard basis are produced for the end consumer. In a strictly regulated European health segment, PhytoVista has also established itself as one of the continent's top three CBD and hemp testing laboratories.

    The Goodbody Wellness segment is experiencing a boom due to the newly emerged Omicron variant and is growing at an impressive rate. Goodbody Wellness clinics provide services - including COVID testing - to clinics and direct-to-consumer and direct-to-business services via telemedicine consultation. The network now includes more than 140 clinics, including facilities supported by Superdrug. Goodbody clinics will continue to provide blood testing while responding to recent government guidance on the new COVID-19 Omicron variant. A collaboration was recently established with Superdrug to offer a full range of blood testing services. The agreement includes 40 Superdrug sites where trained nurses draw blood for a range of tests.

    The beginning of December saw the best week ever in terms of bookings, with several days breaking previous records. As a result, the Company has generated more than EUR 16.25 million in revenue in the eleven months to the end of November.

    Sativa Wellness is fully on track with its three-pillar model, shown by the impressive sales figures for the third quarter and a turnaround in earnings. With a market capitalization of EUR 18.16 million, we believe the stock is undervalued compared to its peer group. Interested investors should take a closer look at the Company.

    Bayer - Positives and glyphosate

    Positive news continues to come from the Pharmaceuticals Division of Bayer AG. The diabetes drug, Finerenone is about to receive EU approval, and there is also good news from the No. 1 sales driver, the blood thinner Xarelto (Rivaroxaban). Xarelto may now be administered in two additional indications in the United States. Bayer received approval from the Food and Drug Administration (FDA).

    The orally available anticoagulant may now be used to treat venous thromboembolism, and as prophylaxis against its recurrence in pediatric patients under 18 years of age after at least 5 days of initial parenteral anticoagulation therapy, the Leverkusen-based Company wrote in a press release. In addition, the health authority approved the use of the drug for thromboprophylaxis after Fontan surgery in patients two years and older with congenital heart disease. According to analyst estimates, Xarelto sales were EUR 4.69 billion in the current year, with revenues expected to reach EUR 4.93 billion in 2022.

    There is still no urgency to engage, given the uncertainties that prevail regarding the glyphosate trial.


    Corona is entering its next wave, and vaccine manufacturers continue to generate recurring revenue from booster vaccines. Novavax is the fifth approved vaccine in the EU and could appeal to vaccine skeptics. Sativa Wellness benefits from expanded testing measures, and uncertainty continues at Bayer due to the Monsanto deal.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

    Ayurcann, Novavax, Covestro - The stragglers are coming!

    • Cannabis

    Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

    Read

    Commented by Stefan Feulner on January 12th, 2022 | 12:54 CET

    Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

    • Cannabis

    About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.

    Read

    Commented by Stefan Feulner on December 28th, 2021 | 07:10 CET

    Upcoming hydrogen and cannabis boom - Nel ASA, Ayurcann, Canopy Growth

    • Cannabis

    These two completely different sectors have one thing in common. After both cannabis stocks and hydrogen sector companies multiplied in the past, a significant correction set in during the stock market year soon ending. This correction is likely to continue into the new year 2022. In the long term, however, there are outstanding opportunities both for cannabis, through legalization in various European countries, and for hydrogen, urgently needed for the energy transition. It is time to position yourself.

    Read